Remimazolam vs Desflurane for General Anesthesia for Ablation of Arrhythmia

Seoul National University Bundang Hospital96 enrolled

Overview

In anesthesia for ablation for cardiac arrhythmias, abrupt hemodynamic changes or fatal arrhythmias can be seen frequently. Remimazolam is a novel ultra-short acting benzodiazepine that provides good hemodynamic stability compared to conventional anesthetic agents. This study aims to investigate whether remimazolam reduces vasoactive agent use during cryo/radiofrequancy ablation under general anesthesia, compared to desflurane(RCT).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Remimazolam Desflurane Cryoablation Arrhythmia General Anesthesia

Eligibility

Sex: ALLMin age: 20 YearsMax age: 105 Years

Medical Language ↔ Plain English

Inclusion Criteria: * =or \> 20 years * Admission for General anesthesia for RFCA or cryoablation procedure Exclusion Criteria: * No severe adverse effect history or hypersensitivity of benzodiazepines or its additives * Acute alcoholic intoxication state * Coma or shock state due to other condition than heart problem. * Acute narrow-angle glaucoma

Outcomes

Primary Outcomes

Vasopressor CIV

Vasopressor CIV or not

Time frame: During anesthesia

Hypotension event

Time frame: During and after anesthesia

Vasopressor (total amount)

Norepinephrine equivalent dose

Time frame: During anesthesia

Secondary Outcomes

Induction time

Induction dose administration\~LOC

Time frame: Induction

Recovery time

Reversal agent administration\~extubation

Time frame: Recovery

Adverse event

Adverse event (desaturation, vomiting, hypotension, bleeding, allergic or anaphylaxis, etc.)

Time frame: During and after anesthesia (~24hr)